MXPA05012850A - Compuestos de anfetamina resistentes al abuso. - Google Patents
Compuestos de anfetamina resistentes al abuso.Info
- Publication number
- MXPA05012850A MXPA05012850A MXPA05012850A MXPA05012850A MXPA05012850A MX PA05012850 A MXPA05012850 A MX PA05012850A MX PA05012850 A MXPA05012850 A MX PA05012850A MX PA05012850 A MXPA05012850 A MX PA05012850A MX PA05012850 A MXPA05012850 A MX PA05012850A
- Authority
- MX
- Mexico
- Prior art keywords
- amphetamine
- lysine
- oral
- administration
- bioavailability
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
- C07C237/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K4/00—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/901—Drugs of abuse, e.g. narcotics, amphetamine
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/17—Nitrogen containing
- Y10T436/173845—Amine and quaternary ammonium
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US47392903P | 2003-05-29 | 2003-05-29 | |
| US56780104P | 2004-05-05 | 2004-05-05 | |
| PCT/US2004/017204 WO2005000334A1 (en) | 2003-05-29 | 2004-06-01 | Abuse resistant amphetamine compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA05012850A true MXPA05012850A (es) | 2006-05-17 |
Family
ID=33555349
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA05012850A MXPA05012850A (es) | 2003-05-29 | 2004-06-01 | Compuestos de anfetamina resistentes al abuso. |
Country Status (25)
Families Citing this family (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6716452B1 (en) * | 2000-08-22 | 2004-04-06 | New River Pharmaceuticals Inc. | Active agent delivery systems and methods for protecting and administering active agents |
| US20070060500A1 (en) * | 2000-08-22 | 2007-03-15 | New River Pharmaceuticals Inc. | Pharmaceutical compositions for prevention of overdose or abuse |
| US8394813B2 (en) * | 2000-11-14 | 2013-03-12 | Shire Llc | Active agent delivery systems and methods for protecting and administering active agents |
| US7375082B2 (en) * | 2002-02-22 | 2008-05-20 | Shire Llc | Abuse-resistant hydrocodone compounds |
| US20060014697A1 (en) * | 2001-08-22 | 2006-01-19 | Travis Mickle | Pharmaceutical compositions for prevention of overdose or abuse |
| US7169752B2 (en) * | 2003-09-30 | 2007-01-30 | New River Pharmaceuticals Inc. | Compounds and compositions for prevention of overdose of oxycodone |
| US20070066537A1 (en) * | 2002-02-22 | 2007-03-22 | New River Pharmaceuticals Inc. | Compounds and compositions for prevention of overdose of oxycodone |
| US7338939B2 (en) * | 2003-09-30 | 2008-03-04 | New River Pharmaceuticals Inc. | Abuse-resistant hydrocodone compounds |
| US7105486B2 (en) * | 2002-02-22 | 2006-09-12 | New River Pharmaceuticals Inc. | Abuse-resistant amphetamine compounds |
| US7700561B2 (en) * | 2002-02-22 | 2010-04-20 | Shire Llc | Abuse-resistant amphetamine prodrugs |
| US7659253B2 (en) * | 2002-02-22 | 2010-02-09 | Shire Llc | Abuse-resistant amphetamine prodrugs |
| US8133881B2 (en) * | 2003-01-13 | 2012-03-13 | Shire Llc | Carbohydrate conjugates to prevent abuse of controlled substances |
| PT1644019E (pt) * | 2003-05-29 | 2012-05-23 | Shire Llc | Compostos de anfetamina resistentes ao abuso |
| CA2540678C (en) * | 2003-09-30 | 2011-02-22 | New River Pharmaceuticals Inc. | Pharmaceutical compositions for prevention of overdose or abuse |
| EP2101571B1 (en) * | 2006-12-11 | 2011-05-18 | Kempharm, Inc. | Ornithine conjugates of amphetamine and processes for making and using the same |
| WO2008098151A2 (en) * | 2007-02-08 | 2008-08-14 | Kempharm, Inc. | Polar hydrophilic prodrugs of amphetamine and other stimulants and processes for making and using the same |
| ES2692437T3 (es) * | 2007-08-13 | 2018-12-03 | Abuse Deterrent Pharmaceutical Llc | Fármacos resistentes al abuso, método de uso y método de preparación |
| WO2009035473A2 (en) * | 2007-09-13 | 2009-03-19 | Sanfilippo Louis C | Method of treating binge eating disorder, obesity resulting from binge eating behavior and depressive disorders |
| CN101555214B (zh) * | 2008-04-08 | 2012-07-11 | 北京嘉事联博医药科技有限公司 | 苯基环丁基酰胺衍生物及其光学异构体、制备方法和用途 |
| BRPI0919711A2 (pt) | 2008-10-17 | 2015-12-08 | Pharmacofore Inc | composições farmacêuticas com liberação atenuada de opióides fenólicos |
| AU2010252740A1 (en) * | 2009-05-26 | 2012-01-12 | Shire Llc | Methods of enhancing selective serotonin reuptake inhibitor effects in mammals |
| US8614346B2 (en) | 2009-06-19 | 2013-12-24 | Cambrex Charles City, Inc. | Methods and compositions for preparation of amphetamine conjugates and salts thereof |
| WO2011031350A1 (en) | 2009-09-08 | 2011-03-17 | Pharmacofore, Inc. | Compositions comprising enzyme-cleavable ketone-modified opioid prodrugs and optional inhibitors thereof |
| EP2501234B1 (en) * | 2009-11-20 | 2017-09-13 | Tonix Pharma Holdings Limited | Methods and compositions for treating symptoms associated with post-traumatic stress disorder using cyclobenzaprine |
| JP5094832B2 (ja) * | 2009-12-25 | 2012-12-12 | 日東電工株式会社 | 粘着剤組成物および粘着シート |
| US20110262355A1 (en) | 2010-04-21 | 2011-10-27 | Jenkins Thomas E | Compositions comprising enzyme-cleavable opioid prodrugs and inhibitors thereof |
| WO2011133348A1 (en) * | 2010-04-21 | 2011-10-27 | Pharmacofore, Inc. | Compositions comprising enzyme-cleavable amphetamine prodrugs and inhibitors thereof |
| WO2011133347A1 (en) * | 2010-04-21 | 2011-10-27 | Pharmacofore, Inc. | Compositions comprising trypsin-cleavable amphetamine prodrugs and inhibitors thereof |
| US9238020B2 (en) | 2010-04-21 | 2016-01-19 | Signature Therapeutics, Inc. | Compositions comprising enzyme-cleavable phenol-modified tapentadol prodrug |
| ES2687095T3 (es) | 2010-05-21 | 2018-10-23 | Research Triangle Institute | Fenilimorfolinas y análogos de las mismas |
| US20110319389A1 (en) | 2010-06-24 | 2011-12-29 | Tonix Pharmaceuticals, Inc. | Methods and compositions for treating fatigue associated with disordered sleep using very low dose cyclobenzaprine |
| US20120010216A1 (en) * | 2010-07-06 | 2012-01-12 | Brown Arthur M | Pharmaceutical compositions containing vanoxerine |
| US20130217615A1 (en) | 2010-10-28 | 2013-08-22 | Shire Llc | Combination treatment of major depressive disorder |
| US8779191B2 (en) * | 2010-12-20 | 2014-07-15 | Cambrex Charles City, Inc. | Methods and compositions for preparing lisdexamfetamine and salts thereof |
| ES2584634T3 (es) | 2011-01-11 | 2016-09-28 | Signature Therapeutics, Inc. | Composiciones que comprenden un profármaco de oxicodona escindible enzimáticamente |
| US8497237B2 (en) | 2011-01-11 | 2013-07-30 | Signature Therapeutics, Inc. | Compositions comprising enzyme-cleavable oxycodone prodrug |
| BR112013022946A2 (pt) | 2011-03-09 | 2017-07-18 | Signature Therapeutics Inc | pró-fármacos de agentes ativos com ligantes heterocíclocos |
| US8685916B2 (en) | 2011-03-09 | 2014-04-01 | Signature Therapeutics, Inc. | Opioid prodrugs with heterocyclic linkers |
| US11241391B2 (en) | 2011-03-23 | 2022-02-08 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
| US9283214B2 (en) | 2011-03-23 | 2016-03-15 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
| US10292937B2 (en) | 2011-03-23 | 2019-05-21 | Ironshore Pharmaceuticals & Development, Inc. | Methods of treatment of attention deficit hyperactivity disorder |
| US8916588B2 (en) | 2011-03-23 | 2014-12-23 | Ironshore Pharmaceuticals & Development, Inc. | Methods for treatment of attention deficit hyperactivity disorder |
| US9119809B2 (en) | 2011-03-23 | 2015-09-01 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
| DK4011364T3 (da) | 2011-03-23 | 2024-03-18 | Ironshore Pharmaceuticals & Dev Inc | Fremgangsmåder og sammensætninger til behandling af ADD (Attention Deficit Disorder) |
| US10905652B2 (en) | 2011-03-23 | 2021-02-02 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
| US9603809B2 (en) | 2011-03-23 | 2017-03-28 | Ironshore Pharmaceuticals & Development, Inc. | Methods of treatment of attention deficit hyperactivity disorder |
| US9498447B2 (en) | 2011-03-23 | 2016-11-22 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
| US8927010B2 (en) | 2011-03-23 | 2015-01-06 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
| WO2013011526A1 (en) * | 2011-07-20 | 2013-01-24 | Ind-Swift Laboratories Limited | Process for preparation of lisdexamphetamine and salts thereof |
| US11571390B2 (en) | 2013-03-15 | 2023-02-07 | Othemo Life Sciences, Inc. | Abuse deterrent compositions and methods of use |
| US10117936B2 (en) | 2013-03-15 | 2018-11-06 | Tonix Pharma Holdings Limited | Eutectic formulations of cyclobenzaprine hydrochloride and amitriptyline hydrochloride |
| US11123310B2 (en) | 2017-02-24 | 2021-09-21 | Pharmapotheca, Llc | Amphetamine controlled release, prodrug, and abuse-deterrent dosage forms |
| US10729685B2 (en) | 2014-09-15 | 2020-08-04 | Ohemo Life Sciences Inc. | Orally administrable compositions and methods of deterring abuse by intranasal administration |
| CA2961822A1 (en) | 2014-09-18 | 2016-03-24 | Tonix Pharma Holdings Limited | Eutectic formulations of cyclobenzaprine hydrochloride |
| US10544434B2 (en) | 2015-06-29 | 2020-01-28 | Noramco, Inc. | Process for the preparation of lisdexamfetamine and related derivatives |
| MX2019006670A (es) * | 2016-12-11 | 2019-12-16 | Kempharm Inc | Composiciones que comprenden profarmacos de metilfenidato, procedimientos para la elaboracion y uso de los mismos. |
| EP3459538B1 (en) | 2017-09-20 | 2020-05-06 | Sandoz AG | Crystalline salts of a dextroamphetamine prodrug |
| AU2018351936A1 (en) * | 2017-10-06 | 2020-05-14 | Fundação Calouste Gulbenkian | Treatment of obesity-related conditions |
| GB2571696B (en) | 2017-10-09 | 2020-05-27 | Compass Pathways Ltd | Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced |
| CA3083341A1 (en) | 2017-12-11 | 2019-06-20 | Tonix Pharma Holdings Limited | Cyclobenzaprine treatment for agitation, psychosis and cognitive decline in dementia and neurodegenerative conditions |
| US11136295B2 (en) | 2018-10-29 | 2021-10-05 | Kempharm, Inc. | D-amphetamine compounds, compositions, and processes for making and using the same |
| US20220162153A1 (en) * | 2019-03-02 | 2022-05-26 | Chemapotheca, Llc | Process for Making Levoamphetamine |
| WO2020212948A1 (en) | 2019-04-17 | 2020-10-22 | Compass Pathfinder Limited | Methods of treating neurocognitive disorders, chronic pain and reducing inflammation |
| US20220151986A1 (en) | 2020-11-18 | 2022-05-19 | Mind Medicine, Inc. | Mdma prodrugs to assist psychotherapy |
| US20220354822A1 (en) * | 2021-05-05 | 2022-11-10 | Mind Medicine, Inc. | Mdma enantiomers |
| IL309073A (en) | 2021-06-03 | 2024-02-01 | Arcadia Medicine Inc | Enantiomeric entactogen compounds and methods of their use. |
| WO2024039599A1 (en) * | 2022-08-17 | 2024-02-22 | Transcend Therapeutics, Inc. | Phenethylamines and cathinones precursors |
Family Cites Families (140)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US200300A (en) * | 1878-02-12 | Improvement in instruments for smoothing and leveling the teeth of horses | ||
| US3028395A (en) * | 1955-03-28 | 1962-04-03 | Parke Davis & Co | Process for the resolution of optically active acids |
| US3028430A (en) * | 1955-03-28 | 1962-04-03 | Parke Davis & Co | Process for the production of optically active isomers of amphetamine |
| DE1493824A1 (de) | 1964-01-27 | 1969-05-22 | Hoffmann La Roche | Verfahren zur Herstellung von Aminocarbonsaeureamiden |
| CH406567A (de) | 1964-02-10 | 1966-01-31 | Inventio Ag | Einrichtung zur Steuerung der Sollwertgrösse während des Verzögerungsvorganges bei Aufzügen mit drehzahlgeregeltem Antrieb |
| GB1112347A (en) | 1965-08-20 | 1968-05-01 | Pierre Wirth | Salts of organic bases with n-carbamyl-l-glutamic acid |
| GB1091089A (en) | 1965-08-20 | 1967-11-15 | Pierre Wirth | Organic base salts of n-carbamyl-aspartic acids |
| US3846399A (en) * | 1969-04-10 | 1974-11-05 | Merck & Co Inc | Process for controlled stepwise synthesis of polypeptides |
| US3676492A (en) * | 1970-12-09 | 1972-07-11 | Aldrich Chem Co Inc | Amino acid amides of disubstituted phenethylamines |
| US3843796A (en) † | 1971-04-26 | 1974-10-22 | Merck & Co Inc | Antihypertensive agents |
| US3706831A (en) * | 1971-05-14 | 1972-12-19 | Abbott Lab | Method for treatment of drug addiction |
| US3975342A (en) * | 1972-05-15 | 1976-08-17 | Biological Developments, Inc. | Tyrosyl-class antigenic conjugates, their preparation and antibodies raised thereto |
| US3884898A (en) * | 1972-08-18 | 1975-05-20 | Syva Co | Normorphine derivatives bonded to proteins |
| US3843696A (en) * | 1972-09-05 | 1974-10-22 | Syva Co | Methadone analog compounds |
| US3878187A (en) * | 1972-09-11 | 1975-04-15 | Syva Co | Polypeptide derivatives of amphetamine and analogs for immunoassays |
| US3878487A (en) * | 1973-08-02 | 1975-04-15 | Alexandr Lvovich Irzhavsky | Electromechanical disc filter |
| US3998799A (en) * | 1973-11-02 | 1976-12-21 | Interx Research Corporation | Novel, transient pro-drug forms of l-dopa |
| US3945342A (en) * | 1973-11-08 | 1976-03-23 | Xerox Corporation | Magnetic brush support member |
| US4040907A (en) * | 1974-06-20 | 1977-08-09 | Syva Company | Iodothyronine enzyme conjugates |
| GB1507144A (en) * | 1974-07-10 | 1978-04-12 | Post Office | Apparatus for drawing dielectric optical waveguides |
| US4000280A (en) * | 1974-08-14 | 1976-12-28 | Astra Lakemedel Aktiebolag | Pharmaceutical compositions containing an amphetamine derivative for the alleviation of anxiety or treatment of depression |
| DE2449333A1 (de) * | 1974-10-17 | 1976-04-29 | Bosch Gmbh Robert | Kraftstoffeinspritzpumpe fuer brennkraftmaschinen |
| US4025501A (en) * | 1975-03-20 | 1977-05-24 | Syva Company | Polypeptide propoxyphene derivatives for immunoassay reagents |
| US4064235A (en) * | 1975-08-21 | 1977-12-20 | Eisai Co., Ltd. | Dopamine derivative compounds, preparation thereof and medicine containing same |
| US4043989A (en) * | 1975-09-11 | 1977-08-23 | Syva Company | Oxazepam derivatives for immunoassay reagents |
| US4064236A (en) * | 1975-12-23 | 1977-12-20 | Merck & Co., Inc. | Peptide carbazates and pharmaceutical composition |
| GB1592552A (en) * | 1976-12-10 | 1981-07-08 | Inst Nat Sante Rech Med | Pseudopeptides used as medicaments |
| JPS54155675A (en) * | 1978-05-30 | 1979-12-07 | Matsushita Electronics Corp | Small-sized fluorescent lamp |
| JPS557242A (en) | 1978-06-30 | 1980-01-19 | Tanabe Seiyaku Co Ltd | Phenethylamine derivative |
| JPS5528915A (en) | 1978-08-18 | 1980-02-29 | Tanabe Seiyaku Co Ltd | Benzyl alcohol derivative and its preparation |
| US4356166A (en) * | 1978-12-08 | 1982-10-26 | University Of Utah | Time-release chemical delivery system |
| DE3008265A1 (de) * | 1980-03-04 | 1981-09-17 | Siemens AG, 1000 Berlin und 8000 München | Verfahren zum sichtbarmachen von stationaeren waermeuebergangskoeffizientenfeldern auf photochemischem wege |
| US4399121A (en) * | 1981-11-04 | 1983-08-16 | Miles Laboratories, Inc. | Iodothyronine immunogens and antibodies |
| US4427660A (en) * | 1982-03-03 | 1984-01-24 | Research Corporation | Formyl-methionyl chemotatic peptide antibiotic conjugates useful in treating infections |
| HU185535B (en) * | 1982-05-25 | 1985-02-28 | Mta Koezponti Hivatala | Process for preparing new gonadoliberin derivatives |
| US4457907A (en) * | 1982-08-05 | 1984-07-03 | Clear Lake Development Group | Composition and method for protecting a therapeutic drug |
| US4650675A (en) * | 1983-08-18 | 1987-03-17 | The Children's Medical Center Corporation | Oligonucleotide conjugates |
| JPS60166657A (ja) * | 1984-02-10 | 1985-08-29 | Nitto Boseki Co Ltd | アルギニル−３−カルボキシ−４−ヒドロキシアニリド |
| EP0179023B1 (fr) * | 1984-10-19 | 1991-01-23 | Battelle Memorial Institute | Polypeptide biodégradable et son utilisation pour le relargage progressif de médicaments |
| GB8500209D0 (en) | 1985-01-04 | 1985-02-13 | Ceskoslovenska Akademie Ved | Synthetic polymeric drugs |
| US4863735A (en) * | 1985-02-19 | 1989-09-05 | Massachusetts Institute Of Technology | Biodegradable polymeric drug delivery system with adjuvant activity |
| US4902505A (en) * | 1986-07-30 | 1990-02-20 | Alkermes | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
| US4801575A (en) * | 1986-07-30 | 1989-01-31 | The Regents Of The University Of California | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
| IN165717B (US07662787-20100216-C00001.png) * | 1986-08-07 | 1989-12-23 | Battelle Memorial Institute | |
| DK406686D0 (da) * | 1986-08-26 | 1986-08-26 | Hans Bundgaard | Carboxylsyrederivater |
| US5994392A (en) * | 1988-02-26 | 1999-11-30 | Neuromedica, Inc. | Antipsychotic prodrugs comprising an antipsychotic agent coupled to an unsaturated fatty acid |
| US5169933A (en) * | 1988-08-15 | 1992-12-08 | Neorx Corporation | Covalently-linked complexes and methods for enhanced cytotoxicity and imaging |
| US5233025A (en) * | 1988-09-02 | 1993-08-03 | Matsushita Electric Industrial Co., Ltd. | Amphetamine protein complex as immunogen for obtaining antibodies specific to methamphetamine |
| US5026827A (en) * | 1988-09-02 | 1991-06-25 | Matsushita Electric Industrial Co., Ltd. | Amphetamine-protein complex as immunogen for obtaining antibodies specific to methamphetamine |
| US4960790A (en) * | 1989-03-09 | 1990-10-02 | University Of Kansas | Derivatives of taxol, pharmaceutical compositions thereof and methods for the preparation thereof |
| FR2649247B1 (fr) * | 1989-06-30 | 1991-09-13 | Thomson Csf | Detecteur infrarouge a base de materiau pyroelectrique |
| US5767227A (en) | 1989-11-03 | 1998-06-16 | Lotus Biochemical Corp. | Iodothyronine polymers |
| US5219564A (en) * | 1990-07-06 | 1993-06-15 | Enzon, Inc. | Poly(alkylene oxide) amino acid copolymers and drug carriers and charged copolymers based thereon |
| JPH078853B2 (ja) | 1990-08-30 | 1995-02-01 | 田辺製薬株式会社 | ドーパミン誘導体の製法 |
| IT1244873B (it) * | 1990-09-12 | 1994-09-12 | Depha Team Srl | Derivati dell'acido 5-aminosalicilico (5-asa) per la terapia delle infiammazioni croniche intestinali |
| DE69103503T2 (de) | 1990-09-28 | 1995-01-05 | Mercian Corp | Adriamycinderivate. |
| US5238714A (en) | 1990-10-02 | 1993-08-24 | Board Of Regents, The University Of Texas System | Efficient microcapsule preparation and method of use |
| US5863899A (en) * | 1991-04-01 | 1999-01-26 | Cortech, Inc. | Bradykinin antagonists |
| JP2613502B2 (ja) * | 1991-05-31 | 1997-05-28 | 東洋紡績株式会社 | 制振材料用粘弾性樹脂組成物 |
| US5811447A (en) | 1993-01-28 | 1998-09-22 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
| US5470997A (en) * | 1992-04-06 | 1995-11-28 | Biosite Diagnostics Incorporated | Amphetamine derivatives and protein and polypeptide amphetamine derivative conjugates and labels |
| US5811127A (en) * | 1992-06-15 | 1998-09-22 | Emisphere Technologies, Inc. | Desferrioxamine oral delivery system |
| CA2096495C (en) * | 1992-06-16 | 2002-07-09 | Kathy Palmer Ordonez | Dual analyte immunoassay |
| GB9213077D0 (en) | 1992-06-19 | 1992-08-05 | Erba Carlo Spa | Polymerbound taxol derivatives |
| US5534496A (en) | 1992-07-07 | 1996-07-09 | University Of Southern California | Methods and compositions to enhance epithelial drug transport |
| GB9215780D0 (en) | 1992-07-24 | 1992-09-09 | Univ London Pharmacy | Peptide compounds |
| US6093391A (en) | 1992-10-08 | 2000-07-25 | Supratek Pharma, Inc. | Peptide copolymer compositions |
| US5298410A (en) * | 1993-02-25 | 1994-03-29 | Sterling Winthrop Inc. | Lyophilized formulation of polyethylene oxide modified proteins with increased shelf-life |
| US5891459A (en) | 1993-06-11 | 1999-04-06 | The Board Of Trustees Of The Leland Stanford Junior University | Enhancement of vascular function by modulation of endogenous nitric oxide production or activity |
| JPH09501655A (ja) * | 1993-08-02 | 1997-02-18 | コモンウェルス サイエンティフィック アンド インダストリアル リサーチ オーガニゼーション | 治療化合物−脂肪酸接合体 |
| AU5722694A (en) | 1993-11-05 | 1995-05-23 | Astra Aktiebolag | Novel amino acid derivatives |
| GB9401891D0 (en) | 1994-02-01 | 1994-03-30 | Boots Co Plc | Therapeutic agents |
| US6051685A (en) * | 1994-03-11 | 2000-04-18 | Daiichi Pharmaceuticals Co., Ltd. | Peptide derivatives |
| RU2152787C2 (ru) * | 1994-06-02 | 2000-07-20 | Дан Рига | Лекарство против стресса, против снижения уровня активности и против старения и способ его получения |
| JP2526811B2 (ja) | 1994-07-22 | 1996-08-21 | 田辺製薬株式会社 | フェネチルアミン誘導体及びその製法 |
| US5716614A (en) | 1994-08-05 | 1998-02-10 | Molecular/Structural Biotechnologies, Inc. | Method for delivering active agents to mammalian brains in a complex with eicosapentaenoic acid or docosahexaenoic acid-conjugated polycationic carrier |
| US5910569A (en) | 1994-11-22 | 1999-06-08 | Lotus Biochemical Corporation | Iodothyronine polymers |
| DE19504387A1 (de) * | 1995-02-11 | 1996-08-22 | Dufa Deutsche Uhrenfabr Gmbh | Schrittmotor |
| US5846743A (en) | 1995-02-22 | 1998-12-08 | Brigham And Women's Hospital, Inc. | Polyphoshoinositide binding peptides for intracellular drug delivery |
| US5670477A (en) | 1995-04-20 | 1997-09-23 | Joseph F. Poduslo | Method to enhance permeability of the blood/brain blood/nerve bariers to therapeutic agents |
| WO1996040123A1 (en) | 1995-06-07 | 1996-12-19 | Swadesh Joel K | Antigen-processing cell-targeted conjugates |
| DE19526274A1 (de) * | 1995-07-19 | 1997-01-23 | Bayer Ag | Verbesserung der Verträglichkeit von pharmazeutisch wirksamen beta-Aminosäuren |
| US5762909A (en) | 1995-08-31 | 1998-06-09 | General Electric Company | Tumor targeting with polymeric molecules having extended conformation |
| US5851536A (en) | 1995-11-22 | 1998-12-22 | University Of Washington | Therapeutic delivery using compounds self-assembled into high axial ratio microstructures |
| US6361957B1 (en) * | 1999-08-03 | 2002-03-26 | Glytech, Inc. | Assay for D-serine transport antagonist and use for treating psychosis |
| CN1149286C (zh) * | 1995-12-28 | 2004-05-12 | 武田药品工业株式会社 | G蛋白偶联受体蛋白的配体多肽及其生产方法和用途 |
| JP3737518B2 (ja) | 1996-03-12 | 2006-01-18 | ピージー−ティーエックスエル カンパニー， エル．ピー． | 水溶性パクリタキセルプロドラッグ |
| US6030941A (en) | 1996-05-01 | 2000-02-29 | Avi Biopharma, Inc. | Polymer composition for delivering substances in living organisms |
| US5922695A (en) | 1996-07-26 | 1999-07-13 | Gilead Sciences, Inc. | Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability |
| US5952294A (en) | 1996-07-31 | 1999-09-14 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Peptidyl prodrugs and methods of making and using the same |
| US6013633A (en) | 1997-08-07 | 2000-01-11 | University Of Cincinnati | Compounds for control of appetite, blood pressure, cardiovascular response, libido, and circadian rhythm |
| DE19640970A1 (de) * | 1996-10-04 | 1998-04-16 | Bayer Ag | Modifizierte Cytostatika |
| US5948750A (en) | 1996-10-30 | 1999-09-07 | Merck & Co., Inc. | Conjugates useful in the treatment of prostate cancer |
| EP0975370B9 (en) | 1997-05-21 | 2004-11-03 | The Board Of Trustees Of The Leland Stanford Junior University | Composition and method for enhancing transport across biological membranes |
| TW460478B (en) | 1997-08-15 | 2001-10-21 | Chugai Pharmaceutical Co Ltd | Phenethylamine derivatives |
| WO1999030727A1 (en) | 1997-12-17 | 1999-06-24 | Enzon, Inc. | Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents |
| US6784186B1 (en) | 1998-01-29 | 2004-08-31 | Roy W. Jackson | Therapeutic compounds |
| US6686446B2 (en) * | 1998-03-19 | 2004-02-03 | The Regents Of The University Of California | Methods and compositions for controlled polypeptide synthesis |
| US6632922B1 (en) * | 1998-03-19 | 2003-10-14 | The Regents Of The University Of California | Methods and compositions for controlled polypeptide synthesis |
| US6680365B1 (en) * | 1998-03-19 | 2004-01-20 | The Regents Of The University Of California | Methods and compositions for controlled polypeptide synthesis |
| US6048736A (en) | 1998-04-29 | 2000-04-11 | Kosak; Kenneth M. | Cyclodextrin polymers for carrying and releasing drugs |
| US6473669B2 (en) * | 1998-07-03 | 2002-10-29 | Kimberly-Clark Worldwide, Inc. | Controlling web tension, and accumulating lengths of web, by actively controlling velocity and acceleration of a festoon |
| US6696558B2 (en) * | 1998-09-09 | 2004-02-24 | The Burnham Institute | Bag proteins and nucleic acid molecules encoding them |
| JP2000173537A (ja) * | 1998-09-29 | 2000-06-23 | Toshiba Lighting & Technology Corp | 低圧水銀蒸気放電灯および照明装置 |
| US7083808B2 (en) * | 1998-12-17 | 2006-08-01 | Euro-Celtique S.A. | Controlled/modified release oral methylphenidate formulations |
| US7374779B2 (en) | 1999-02-26 | 2008-05-20 | Lipocine, Inc. | Pharmaceutical formulations and systems for improved absorption and multistage release of active agents |
| US6716452B1 (en) | 2000-08-22 | 2004-04-06 | New River Pharmaceuticals Inc. | Active agent delivery systems and methods for protecting and administering active agents |
| US7060708B2 (en) * | 1999-03-10 | 2006-06-13 | New River Pharmaceuticals Inc. | Active agent delivery systems and methods for protecting and administering active agents |
| US6309633B1 (en) | 1999-06-19 | 2001-10-30 | Nobex Corporation | Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same |
| CA2277855A1 (fr) | 1999-07-14 | 2001-01-14 | Solvision | Methode et systeme de mesure de la hauteur des billes de soudure d'un circuit imprime |
| US6384020B1 (en) * | 1999-07-14 | 2002-05-07 | Shire Laboratories, Inc. | Rapid immediate release oral dosage form |
| US6806330B1 (en) * | 1999-12-17 | 2004-10-19 | Dow Global Technologies Inc. | Amine organoborane complex polymerization initiators and polymerizable compositions |
| WO2003034980A2 (en) † | 2000-11-14 | 2003-05-01 | New River Pharmaceuticals Inc. | A novel pharmaceutical compound containing abacavir sulfate and methods of making and using same |
| US20020099013A1 (en) | 2000-11-14 | 2002-07-25 | Thomas Piccariello | Active agent delivery systems and methods for protecting and administering active agents |
| US20070060500A1 (en) * | 2000-08-22 | 2007-03-15 | New River Pharmaceuticals Inc. | Pharmaceutical compositions for prevention of overdose or abuse |
| US20020151526A1 (en) | 2000-10-06 | 2002-10-17 | Gallop Mark A. | Bile-acid prodrugs of L-dopa and their use in the sustained treatment of parkinsonism |
| AU2002211863A1 (en) | 2000-10-06 | 2002-04-15 | Xenoport, Inc. | Bile-acid derived compounds for providing sustained systemic concentrations of drugs after oral administration |
| US20020098999A1 (en) | 2000-10-06 | 2002-07-25 | Gallop Mark A. | Compounds for sustained release of orally delivered drugs |
| WO2002039998A2 (en) * | 2000-11-01 | 2002-05-23 | Sention, Inc. | Methods and compositions for regulating memory consolidation |
| US6472228B2 (en) * | 2000-12-04 | 2002-10-29 | Lifepoint, Inc. | Composition and methods for synthesis of novel tracers for detecting amphetamine and methamphetamine in samples |
| US6740641B2 (en) | 2001-07-27 | 2004-05-25 | Euro-Celtique, S.A. | Sugar derivatives of hydromorphone, dihydromorphine and dihydromorphine, compositions thereof and uses for treating or preventing pain |
| US7169752B2 (en) * | 2003-09-30 | 2007-01-30 | New River Pharmaceuticals Inc. | Compounds and compositions for prevention of overdose of oxycodone |
| US7375082B2 (en) | 2002-02-22 | 2008-05-20 | Shire Llc | Abuse-resistant hydrocodone compounds |
| US20070066537A1 (en) * | 2002-02-22 | 2007-03-22 | New River Pharmaceuticals Inc. | Compounds and compositions for prevention of overdose of oxycodone |
| US20060014697A1 (en) * | 2001-08-22 | 2006-01-19 | Travis Mickle | Pharmaceutical compositions for prevention of overdose or abuse |
| US7338939B2 (en) * | 2003-09-30 | 2008-03-04 | New River Pharmaceuticals Inc. | Abuse-resistant hydrocodone compounds |
| US20030091593A1 (en) * | 2001-09-14 | 2003-05-15 | Cytos Biotechnology Ag | In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles |
| US6399828B1 (en) * | 2001-10-29 | 2002-06-04 | Boehringer Ingelheim Chemicals, Inc. | Preparation of amphetamines from phenylpropanolamines |
| WO2003057716A2 (en) * | 2002-01-08 | 2003-07-17 | New River Pharmaceuticals, Inc. | Dendritic encapsulation of active agents |
| ES2500117T3 (es) * | 2002-02-22 | 2014-09-30 | Shire Llc | Novedosos compuestos farmacéuticos de liberación sostenida para prevenir el abuso de sustancias controladas |
| KR20050010756A (ko) * | 2002-02-22 | 2005-01-28 | 뉴 리버 파마슈티칼스, 인크. | 피험자 간 약물 혈청 농도의 변동성을 감소시키기 위한펩티드-약물 접합체의 용도 |
| US7105486B2 (en) * | 2002-02-22 | 2006-09-12 | New River Pharmaceuticals Inc. | Abuse-resistant amphetamine compounds |
| US7700561B2 (en) * | 2002-02-22 | 2010-04-20 | Shire Llc | Abuse-resistant amphetamine prodrugs |
| US7659253B2 (en) † | 2002-02-22 | 2010-02-09 | Shire Llc | Abuse-resistant amphetamine prodrugs |
| US6913768B2 (en) * | 2002-09-24 | 2005-07-05 | Shire Laboratories, Inc. | Sustained release delivery of amphetamine salts |
| US8133881B2 (en) * | 2003-01-13 | 2012-03-13 | Shire Llc | Carbohydrate conjugates to prevent abuse of controlled substances |
| AR042938A1 (es) * | 2003-02-06 | 2005-07-06 | Wyeth Corp | Uso del cci-779 en el tratamiento de la fibrosis hepatica |
| WO2004082620A2 (en) | 2003-03-13 | 2004-09-30 | Controlled Chemicals, Inc. | Oxycodone conjugates with lower the abuse potential and extended duration of action |
| PT1644019E (pt) | 2003-05-29 | 2012-05-23 | Shire Llc | Compostos de anfetamina resistentes ao abuso |
| CA2540678C (en) * | 2003-09-30 | 2011-02-22 | New River Pharmaceuticals Inc. | Pharmaceutical compositions for prevention of overdose or abuse |
-
2004
- 2004-06-01 PT PT04753925T patent/PT1644019E/pt unknown
- 2004-06-01 PL PL04753925T patent/PL1644019T5/pl unknown
- 2004-06-01 SI SI200431876T patent/SI1644019T2/en unknown
- 2004-06-01 KR KR1020117011654A patent/KR101159477B1/ko active IP Right Grant
- 2004-06-01 CA CA2527646A patent/CA2527646C/en active Active
- 2004-06-01 EA EA200501895A patent/EA010295B1/ru not_active IP Right Cessation
- 2004-06-01 WO PCT/US2004/017204 patent/WO2005000334A1/en active Application Filing
- 2004-06-01 JP JP2006533534A patent/JP4898445B2/ja active Active
- 2004-06-01 EP EP04753925.9A patent/EP1644019B2/en active Active
- 2004-06-01 BR BRPI0410792A patent/BRPI0410792B8/pt active IP Right Grant
- 2004-06-01 ES ES04753925.9T patent/ES2380622T5/es active Active
- 2004-06-01 AU AU2004251647A patent/AU2004251647B2/en active Active
- 2004-06-01 CN CN2004800190890A patent/CN1816346B/zh active Active
- 2004-06-01 AT AT04753925T patent/ATE545427T2/de active
- 2004-06-01 US US10/857,619 patent/US7223735B2/en active Active
- 2004-06-01 KR KR1020057022852A patent/KR101170840B1/ko active IP Right Grant
- 2004-06-01 NZ NZ544162A patent/NZ544162A/en unknown
- 2004-06-01 MX MXPA05012850A patent/MXPA05012850A/es active IP Right Grant
- 2004-06-01 DK DK04753925.9T patent/DK1644019T4/en active
-
2005
- 2005-11-27 EG EGPCTNA2005000769A patent/EG26032A/en active
- 2005-11-28 IL IL172212A patent/IL172212A/en active IP Right Grant
- 2005-12-28 NO NO20056211A patent/NO20056211L/no not_active Application Discontinuation
-
2006
- 2006-09-20 HK HK06110426.7A patent/HK1088254A1/xx active IP Right Maintenance
-
2007
- 2007-05-07 US US11/745,019 patent/US7662787B2/en active Active
-
2008
- 2008-08-29 US US12/201,739 patent/US7678770B2/en not_active Expired - Lifetime
- 2008-08-29 US US12/202,096 patent/US7718619B2/en not_active Expired - Lifetime
- 2008-09-02 US US12/203,136 patent/US20090209471A1/en not_active Abandoned
- 2008-09-02 US US12/203,108 patent/US20090181898A1/en not_active Abandoned
- 2008-09-02 US US12/202,987 patent/US20090192093A1/en not_active Abandoned
- 2008-09-26 US US12/239,180 patent/US20090186825A1/en not_active Abandoned
- 2008-09-26 US US12/239,087 patent/US20090186828A1/en not_active Abandoned
- 2008-09-26 US US12/239,400 patent/US20090186945A1/en not_active Abandoned
-
2009
- 2009-10-21 US US12/582,838 patent/US20100105781A1/en not_active Abandoned
-
2011
- 2011-10-04 JP JP2011219941A patent/JP2012006978A/ja active Pending
-
2012
- 2012-04-11 CY CY20121100360T patent/CY1113130T1/el unknown
-
2019
- 2019-11-26 NL NL301019C patent/NL301019I2/nl unknown
-
2020
- 2020-11-10 BE BE2020C543C patent/BE2020C543I2/nl unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MXPA05012850A (es) | Compuestos de anfetamina resistentes al abuso. | |
| US7105486B2 (en) | Abuse-resistant amphetamine compounds | |
| US7375083B2 (en) | Pharmaceutical compositions for prevention of overdose or abuse | |
| US8106016B2 (en) | Compounds and compositions for prevention of overdose of oxycodone | |
| US8343927B2 (en) | Pharmaceutical compositions for prevention of overdose or abuse | |
| US20070060500A1 (en) | Pharmaceutical compositions for prevention of overdose or abuse | |
| US20070066537A1 (en) | Compounds and compositions for prevention of overdose of oxycodone | |
| ZA200602598B (en) | Pharmaceutical compositions for prevention of overdose or abuse | |
| ZA200510383B (en) | Abuse resistant amphetamine compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration | ||
| GB | Transfer or rights |